Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 Jun;65(6):2371–2377. doi: 10.1128/iai.65.6.2371-2377.1997

Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes.

F Afrin 1, N Ali 1
PMCID: PMC175328  PMID: 9169776

Abstract

In the search for a leishmaniasis vaccine, extensive studies of cutaneous leishmaniasis have been carried out. Investigations in this regard with the visceral form are limited. As an initial step in the identification of the protective molecules, leishmanial antigens extracted from the membranes of Leishmania donovani promastigotes, alone or in association with liposomes, were evaluated for their immunogenicity and ability to elicit a protective immune response against challenge infection. Intraperitoneal immunization of hamsters and BALB/c mice with the leishmanial antigens conferred protection against infection with the virulent promastigotes. Encapsulation in positively charged liposomes significantly enhanced the protective efficacy of these antigens. The splenic parasite burden of hamsters was reduced by 97% after 6 months of infection. BALB/c mice exhibited 87 and 81.3% protection in the liver and spleen, respectively, after 4 months of infection. These protected animals elicited profound delayed-type hypersensitivity and increased levels of Leishmania-specific immunoglobulin G (IgG) antibodies. Protection in mice also coincided with elevated levels of IgM and IgA antibodies, which decreased with disease progression in the control-infected animals. Although both IgG1 and IgG2a antibodies were present in the sera of infected mice, IgG1 appeared to be the predominant isotype, suggesting a preferential induction of the Th2 type of immune response over that of Th1. Effective stimulation of all the IgG isotypes, particularly IgG2a, after immunization with liposome encapsulated antigens seems to be responsible for the significant levels of resistance against the disease. Taken together, these data indicate a potential for the liposomal antigens as a vaccine which could trigger both humoral and cell-mediated immune responses.

Full Text

The Full Text of this article is available as a PDF (187.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Afonso L. C., Scharton T. M., Vieira L. Q., Wysocka M., Trinchieri G., Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science. 1994 Jan 14;263(5144):235–237. doi: 10.1126/science.7904381. [DOI] [PubMed] [Google Scholar]
  2. Ali N., Afrin F. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes. J Parasitol. 1997 Feb;83(1):70–75. [PubMed] [Google Scholar]
  3. Basak S. K., Saha B., Bhattacharya A., Roy S. Immunobiological studies on experimental visceral leishmaniasis. II. Adherent cell-mediated down-regulation of delayed-type hypersensitivity response and up-regulation of B cell activation. Eur J Immunol. 1992 Aug;22(8):2041–2045. doi: 10.1002/eji.1830220813. [DOI] [PubMed] [Google Scholar]
  4. Blackwell J. M., Ulczak O. M. Immunoregulation of genetically controlled acquired responses to Leishmania donovani infection in mice: demonstration and characterization of suppressor T cells in noncure mice. Infect Immun. 1984 Apr;44(1):97–102. doi: 10.1128/iai.44.1.97-102.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bretscher P. A., Wei G., Menon J. N., Bielefeldt-Ohmann H. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science. 1992 Jul 24;257(5069):539–542. doi: 10.1126/science.1636090. [DOI] [PubMed] [Google Scholar]
  6. Burns J. M., Jr, Shreffler W. G., Benson D. R., Ghalib H. W., Badaro R., Reed S. G. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):775–779. doi: 10.1073/pnas.90.2.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carvalho E. M., Badaró R., Reed S. G., Jones T. C., Johnson W. D., Jr Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest. 1985 Dec;76(6):2066–2069. doi: 10.1172/JCI112209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Champsi J., McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun. 1988 Dec;56(12):3272–3279. doi: 10.1128/iai.56.12.3272-3279.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Connell N. D., Medina-Acosta E., McMaster W. R., Bloom B. R., Russell D. G. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11473–11477. doi: 10.1073/pnas.90.24.11473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Deplazes P., Smith N. C., Arnold P., Lutz H., Eckert J. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol. 1995 Sep;17(9):451–458. doi: 10.1111/j.1365-3024.1995.tb00914.x. [DOI] [PubMed] [Google Scholar]
  11. Evans T. G., Teixeira M. J., McAuliffe I. T., Vasconcelos I., Vasconcelos A. W., Sousa A. de A., Lima J. W., Pearson R. D. Epidemiology of visceral leishmaniasis in northeast Brazil. J Infect Dis. 1992 Nov;166(5):1124–1132. doi: 10.1093/infdis/166.5.1124. [DOI] [PubMed] [Google Scholar]
  12. Fries L. F., Gordon D. M., Richards R. L., Egan J. E., Hollingdale M. R., Gross M., Silverman C., Alving C. R. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):358–362. doi: 10.1073/pnas.89.1.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ghose A. C., Haldar J. P., Pal S. C., Mishra B. P., Mishra K. K. Serological investigations on Indian kala-azar. Clin Exp Immunol. 1980 May;40(2):318–326. [PMC free article] [PubMed] [Google Scholar]
  14. Ghosh A. K., Bhattacharyya F. K., Ghosh D. K. Leishmania donovani: amastigote inhibition and mode of action of berberine. Exp Parasitol. 1985 Dec;60(3):404–413. doi: 10.1016/0014-4894(85)90047-5. [DOI] [PubMed] [Google Scholar]
  15. Green M. S., Kark J. D., Greenblatt C. L., Londner M. V., Frankenburg S., Jacobson R. L. The cellular and humoral immune response in subjects vaccinated against cutaneous leishmaniasis using Leishmania tropica major promastigotes. Parasite Immunol. 1983 Jul;5(4):337–344. doi: 10.1111/j.1365-3024.1983.tb00749.x. [DOI] [PubMed] [Google Scholar]
  16. Haldar J. P., Ghose S., Saha K. C., Ghose A. C. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect Immun. 1983 Nov;42(2):702–707. doi: 10.1128/iai.42.2.702-707.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Heinzel F. P., Sadick M. D., Mutha S. S., Locksley R. M. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7011–7015. doi: 10.1073/pnas.88.16.7011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ho J. L., Badaró R., Schwartz A., Dinarello C. A., Gelfand J. A., Sobel J., Barral A., Netto M. B., Carvalho E. M., Reed S. G. Diminished in vitro production of interleukin-1 and tumor necrosis factor-alpha during acute visceral leishmaniasis and recovery after therapy. J Infect Dis. 1992 Jun;165(6):1094–1102. doi: 10.1093/infdis/165.6.1094. [DOI] [PubMed] [Google Scholar]
  19. Holaday B. J., Pompeu M. M., Evans T., Braga D. N., Texeira M. J., Sousa A. de Q., Sadick M. D., Vasconcelos A. W., Abrams J. S., Pearson R. D. Correlates of Leishmania-specific immunity in the clinical spectrum of infection with Leishmania chagasi. J Infect Dis. 1993 Feb;167(2):411–417. doi: 10.1093/infdis/167.2.411. [DOI] [PubMed] [Google Scholar]
  20. Holbrook T. W., Cook J. A. Immunization of mice against Leishmania donovani by subcutaneous injections of dead promastigotes. Am J Trop Med Hyg. 1983 Jan;32(1):51–53. doi: 10.4269/ajtmh.1983.32.51. [DOI] [PubMed] [Google Scholar]
  21. Holbrook T. W., Cook J. A., Parker B. W. Immunization against Leishmania donovani: glucan as an adjuvant with killed promastigotes. Am J Trop Med Hyg. 1981 Jul;30(4):762–768. doi: 10.4269/ajtmh.1981.30.762. [DOI] [PubMed] [Google Scholar]
  22. Jaffe C. L., Rachamim N., Sarfstein R. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis. J Immunol. 1990 Jan 15;144(2):699–706. [PubMed] [Google Scholar]
  23. Kahl L. P., Scott C. A., Lelchuk R., Gregoriadis G., Liew F. Y. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization. J Immunol. 1989 Jun 15;142(12):4441–4449. [PubMed] [Google Scholar]
  24. Karp C. L., el-Safi S. H., Wynn T. A., Satti M. M., Kordofani A. M., Hashim F. A., Hag-Ali M., Neva F. A., Nutman T. B., Sacks D. L. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest. 1993 Apr;91(4):1644–1648. doi: 10.1172/JCI116372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kaye P. M., Bancroft G. J. Leishmania donovani infection in scid mice: lack of tissue response and in vivo macrophage activation correlates with failure to trigger natural killer cell-derived gamma interferon production in vitro. Infect Immun. 1992 Oct;60(10):4335–4342. doi: 10.1128/iai.60.10.4335-4342.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kaye P. M., Curry A. J., Blackwell J. M. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol. 1991 Apr 15;146(8):2763–2770. [PubMed] [Google Scholar]
  27. Kemp M., Kurtzhals J. A., Bendtzen K., Poulsen L. K., Hansen M. B., Koech D. K., Kharazmi A., Theander T. G. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun. 1993 Mar;61(3):1069–1073. doi: 10.1128/iai.61.3.1069-1073.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kemp M., Kurtzhals J. A., Christensen C. B., Kharazmi A., Jardim A., Bendtzen K., Gachihi G. S., Olafson R. W., Theander T. G. Production of interferon-gamma and interleukin-4 by human T cells recognizing Leishmania lipophosphoglycan-associated protein. Immunol Lett. 1993 Oct;38(2):137–144. doi: 10.1016/0165-2478(93)90179-6. [DOI] [PubMed] [Google Scholar]
  29. Kemp M., Theander T. G., Kharazmi A. The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example. Immunol Today. 1996 Jan;17(1):13–16. doi: 10.1016/0167-5699(96)80562-7. [DOI] [PubMed] [Google Scholar]
  30. Krowka J., Stites D., Debs R., Larsen C., Fedor J., Brunette E., Düzgünes N. Lymphocyte proliferative responses to soluble and liposome-conjugated envelope peptides of HIV-1. J Immunol. 1990 Apr 1;144(7):2535–2540. [PubMed] [Google Scholar]
  31. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  32. Latif N. A., Mandal C. Liposome as an adjuvant for the production of estradiol antibodies. Immunol Lett. 1987 Jul;15(3):237–242. doi: 10.1016/0165-2478(87)90030-7. [DOI] [PubMed] [Google Scholar]
  33. Latif N., Bachhawat B. K. The effect of surface charges of liposomes in immunopotentiation. Biosci Rep. 1984 Feb;4(2):99–107. doi: 10.1007/BF01120305. [DOI] [PubMed] [Google Scholar]
  34. Mayrink W., Williams P., da Costa C. A., Magalhães P. A., Melo M. N., Dias M., Oliveira Lima A., Michalick M. S., Ferreira Carvalho E., Barros G. C. An experimental vaccine against American dermal leishmaniasis: experience in the State of Espírito Santo, Brazil. Ann Trop Med Parasitol. 1985 Jun;79(3):259–269. doi: 10.1080/00034983.1985.11811917. [DOI] [PubMed] [Google Scholar]
  35. Melby P. C., Andrade-Narvaez F. J., Darnell B. J., Valencia-Pacheco G., Tryon V. V., Palomo-Cetina A. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun. 1994 Mar;62(3):837–842. doi: 10.1128/iai.62.3.837-842.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Meller-Melloul C., Farnarier C., Dunan S., Faugere B., Franck J., Mary C., Bongrand P., Quilici M., Kaplanski S. Evidence of subjects sensitized to Leishmania infantum on the French Mediterranean coast: differences in gamma interferon production between this population and visceral leishmaniasis patients. Parasite Immunol. 1991 Sep;13(5):531–536. doi: 10.1111/j.1365-3024.1991.tb00549.x. [DOI] [PubMed] [Google Scholar]
  37. Miralles G. D., Stoeckle M. Y., McDermott D. F., Finkelman F. D., Murray H. W. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun. 1994 Mar;62(3):1058–1063. doi: 10.1128/iai.62.3.1058-1063.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Murray H. W., Squires K. E., Miralles C. D., Stoeckle M. Y., Granger A. M., Granelli-Piperno A., Bogdan C. Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity. J Immunol. 1992 Mar 15;148(6):1858–1863. [PubMed] [Google Scholar]
  39. Müller I., Pedrazzini T., Farrell J. P., Louis J. T-cell responses and immunity to experimental infection with leishmania major. Annu Rev Immunol. 1989;7:561–578. doi: 10.1146/annurev.iy.07.040189.003021. [DOI] [PubMed] [Google Scholar]
  40. Rachamim N., Jaffe C. L. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J Immunol. 1993 Mar 15;150(6):2322–2331. [PubMed] [Google Scholar]
  41. Reddy R., Zhou F., Nair S., Huang L., Rouse B. T. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J Immunol. 1992 Mar 1;148(5):1585–1589. [PubMed] [Google Scholar]
  42. Reiner N. E. Host-parasite relationship in murine leishmaniasis: pathophysiological and immunological changes. Infect Immun. 1982 Dec;38(3):1223–1230. doi: 10.1128/iai.38.3.1223-1230.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Rivier D., Shah R., Bovay P., Mauel J. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunol. 1993 Feb;15(2):75–84. doi: 10.1111/j.1365-3024.1993.tb00587.x. [DOI] [PubMed] [Google Scholar]
  44. Russell D. G., Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol. 1988 Feb 15;140(4):1274–1279. [PubMed] [Google Scholar]
  45. Scott P., Caspar P., Sher A. Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes. J Immunol. 1990 Feb 1;144(3):1075–1079. [PubMed] [Google Scholar]
  46. Scott P., Pearce E., Natovitz P., Sher A. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J Immunol. 1987 Jul 1;139(1):221–227. [PubMed] [Google Scholar]
  47. Scott P. The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis. Exp Parasitol. 1989 Apr;68(3):369–372. doi: 10.1016/0014-4894(89)90120-3. [DOI] [PubMed] [Google Scholar]
  48. Snapper C. M., Paul W. E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science. 1987 May 22;236(4804):944–947. doi: 10.1126/science.3107127. [DOI] [PubMed] [Google Scholar]
  49. Stern J. J., Oca M. J., Rubin B. Y., Anderson S. L., Murray H. W. Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis. J Immunol. 1988 Jun 1;140(11):3971–3977. [PubMed] [Google Scholar]
  50. Titus R. G., Gueiros-Filho F. J., de Freitas L. A., Beverley S. M. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10267–10271. doi: 10.1073/pnas.92.22.10267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Titus R. G., Lima G. C., Engers H. D., Louis J. A. Exacerbation of murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell populations capable of mediating Leishmania major-specific delayed-type hypersensitivity. J Immunol. 1984 Sep;133(3):1594–1600. [PubMed] [Google Scholar]
  52. White A. C., Jr, McMahon-Pratt D. Prophylactic immunization against experimental Leishmania donovani infection by use of a purified protein vaccine. J Infect Dis. 1990 Jun;161(6):1313–1314. doi: 10.1093/infdis/161.6.1313. [DOI] [PubMed] [Google Scholar]
  53. Wilson M. E., Young B. M., Andersen K. P., Weinstock J. V., Metwali A., Ali K. M., Donelson J. E. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect Immun. 1995 May;63(5):2062–2069. doi: 10.1128/iai.63.5.2062-2069.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Xu D., McSorley S. J., Chatfield S. N., Dougan G., Liew F. Y. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA- AroD-). Immunology. 1995 May;85(1):1–7. [PMC free article] [PubMed] [Google Scholar]
  55. Yang D. M., Rogers M. V., Liew F. Y. Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major. Immunology. 1991 Jan;72(1):3–9. [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES